RecruitingPhase 2NCT06807606

Optimized Cord Blood Transplantation for the Treatment of Patients With High-risk Hematologic Malignancies Who Have Relapsed After First Allogeneic Stem Cell Transplantation

Optimized CBT for Pts With High-risk Hematologic Malignancies Who Have Relapsed After First ASCT


Sponsor

M.D. Anderson Cancer Center

Enrollment

35 participants

Start Date

Mar 3, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The goal of this clinical research study is to learn if intermediate-intensity conditioning therapy followed by a cord blood transplant can help to control high-risk hematological malignancies in patients who need a second allogeneic stem cell transplantation.


Eligibility

Max Age: 60 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Drugs Cyclophosphamide, a drug called Fludarabine, and others for people with hematologic malignancies. The study is currently recruiting participants at 1 location. People eligible for this study include up to age 60 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGDrugs Cyclophosphamide

Given as standard of care treatment through IV infusion

DRUGFludarabine

Given as standard of care treatment through IV infusion

DRUGThiotepa

Given as standard of care treatment through IV infusion

DRUGTacrolimus

Given as standard of care treatment through IV infusion

DRUGMycophenolate mofetil

Given as standard of care treatment through IV infusion


Locations(1)

The University of Texas M. D. Anderson Cancer Center

Houston, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06807606


Related Trials